Dual amylin and calcitonin receptor agonists and uses thereof

Patent metadata

Field	Value
Publication number	US-12558430-B2
Application number	US-202218050659-A
Country	US
Kind code	B2
Filing date	Oct 28, 2022
Priority date	Dec 18, 2020
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

First claim

We claim:

1 . A method of treating a condition selected from the group consisting of diabetes, obesity, non-alcoholic steatohepatitis (NASH), and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) receptor agonist.

2 . The method of claim 1 , wherein the GLP-1 receptor agonist is selected from the group consisting of Compound III (SEQ ID NO:6), Compound VIII (SEQ ID NO:12), and Compound IX (SEQ ID NO:13).

3 . The method of claim 1 , wherein the compound comprising SEQ ID NO: 1 or the pharmaceutically acceptable salt thereof is administered separately from the GLP-1 receptor agonist.

4 . The method of claim 1 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered simultaneously with the GLP-1 receptor agonist.

5 . The method of claim 1 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered sequentially with the GLP-1 receptor agonist.

6 . A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a dual agonist of GLP-1 and gastric inhibitory peptide (GIP) receptors.

7 . The method of claim 6 , wherein the dual agonist of GLP-1 and GIP receptors is selected from the group consisting of Compound VI (SEQ ID NO:9) and Compound VII (SEQ ID NO: 10).

8 . The method of claim 6 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered separately from the dual agonist of GLP-1 and GIP receptors.

9 . The method of claim 6 , wherein the compound comprising SEQ ID NO: 1 or the pharmaceutically acceptable salt thereof is administered simultaneously with the dual agonist of GLP-1 and GIP receptors.

10 . The method of claim 6 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered sequentially with the dual agonist of GLP-1 and GIP receptors.

11 . A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a tri-agonist of glucagon, GIP, and GLP-1 receptors.

12 . The method of claim 11 , wherein the tri-agonist of glucagon, GIP, and GLP-1 receptors is Compound V (SEQ ID NO:8).

13 . The method of claim 11 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered separately from the tri-agonist of glucagon, GIP, and GLP-1 receptors.

14 . The method of claim 11 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered simultaneously with the tri-agonist of glucagon, GIP, and GLP-1 receptors.

15 . The method of claim 11 , wherein the compound comprising SEQ ID NO: 1 or the pharmaceutically acceptable salt thereof is administered sequentially with the tri-agonist of glucagon, GIP, and GLP-1 receptors.

16 . A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of an analog of oxyntomodulin.

17 . The method of claim 16 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered separately from the analog of oxyntomodulin.

18 . The method of claim 16 , wherein the compound comprising SEQ ID NO: 1 or the pharmaceutically acceptable salt thereof is administered simultaneously with the analog of oxyntomodulin.

19 . The method of claim 16 , wherein the compound comprising SEQ ID NO:1 or the pharmaceutically acceptable salt thereof is administered sequentially with the analog of oxyntomodulin.

Assignees

• Lilly Co Eli

Inventors

• Coskun Tamer
• Qu Hongchang

Classifications

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61P3/10 Primary

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K47/54

  the modifying agent being an organic compound · CPC title

• A61K47/545

  Heterocyclic compounds (A61K47/558 takes precedence) · CPC title